TORONTO, ON / ACCESSWIRE / April 18, 2017 / ChroMedX Corp. (CSE: CHX) (OTCQB: MNLIF) (FSE: EIY2) (the "Company"), developer of the HemoPalm Handheld Blood Analyzer System, is pleased to announce the finalization of the new HemoPalm 2.0 design.
The new design reflects the evolution of diagnostics moving from laboratory based analysis to point-of-care testing (POCT). The design includes a number of new and updated features for improving diagnostic time and treatment for patients in the hospital, particularly in the ED and ICU and in the field for use by, for example first responders.
HemoPalm 2.0 Design and Charger
To view an enhanced version of this graphic, please visit:
http://orders.newsfilecorp.com/files/952/26220_chromedx1enhanced.jpg
HemoPalm 2.0 Design Features
- 5" resistive touch screen LCD display for easy navigation and sanitization
- Micro spectrometer and biosensor analyzer
- Wifi and Bluetooth capability enables transmittal of patient data to central hub
- 64-bit quad core CPU
- USB port for manual data transfer
- Memory for storing patient data for hospital and in field use
- 1D & 2 D Barcode reader - for easy cartridge scan and patient armband scan
- Rechargeable battery - lightweight and low profile optimum for handheld in field use
- Mountable charging station
These features and combined analysis offer rapid analysis at patient location and can replace multiple units in the OR as well as expedite triage/treatment in the emergency department and other areas of the hospital. The advanced lightweight design is also critical for in field application.
"Improving patient care is our core mission at ChroMedX and the new HemoPalm design reflects that. Our technology is inspired by the need for reliable POCT. Ease of use and reliability are paramount when offering a new technology to the market place and I believe this design accomplishes that," said Ash Kaushal, President & CEO, ChroMedX Corp.
HemoPalm 2.0 Design
To view an enhanced version of this graphic, please visit:
http://orders.newsfilecorp.com/files/952/26220_chromedx2enhanced.jpg
At present, the combination of tests the HemoPalm will offer are only available on benchtop analyzers usually found in the central laboratory. Analytes the HemoPalm 2.0 system is designed to measure includes Blood gases, CO-oximetry, Electrolytes and Bilirubin, which makes it a valuable tool for use in multiple hospital departments and in field applications for first responders, emerging economies, military and disaster relief.
Patients can present symptoms ranging from shortness of breath to unconsciousness, caused by dysfunction of one or several organs including the lungs, kidney, heart and gastrointestinal tract. Patients can also be victims of environmental conditions such as excessive smoke inhalation (a common cause of carbon monoxide poisoning) or ingestion of nitrates and nitrites that may or may not be medicinal ingredients. The tests below are essential for aiding in the diagnosis of the patients' symptoms, and monitoring their treatment.
First HemoPalm cartridge analysis will include:
- CO-Oximetry: Total Hb, Oxy-Hb, Deoxy-Hb, Met-Hb, and Caboxy-Hb
- Blood Gases: pH, pO2 and pCO2
- Electrolytes: Na+, K+, Cl-
- Bilirubin
- Hemoglobin O2 Sat
- Base Excess (calculated)
- Anion Gap (calculated)
These tests are crucial for determining a patient's oxygenation and acid-base status in emergency situations to identify causes of hypoxemia, or hypoxia, (oxygen deficiency at the tissue level), and conditions such as asthma or chronic obstructive pulmonary disease (COPD) and electrolyte imbalances such as dehydration, kidney disease, lung diseases, or heart conditions.
Bilirubin is particularly important for detecting neonatal jaundice, which is easily treatable, but can cause brain damage and hearing loss if left untreated. Especially in the case of babies, collection of capillary blood is preferred because collection of arterial blood is difficult, painful, and is a major contributor of anemia.
The Company is working now to finalize the cartridge receptor (intake) before completing assembly and packaging of the functional prototype based on the new HemoPalm 2.0 design.
Earlier this month ChroMedX announced the completion of the HemoPalm Cartridge design and is now concentrated on evaluating the manufacturability and reproducibility of large quantities of the cartridge to be used for continued testing, calibration and validation of the HemoPalm analyzer prototype.
About ChroMedX Corp.
ChroMedX Corp. is a medical technology company focused on the development of novel medical devices for in vitro diagnostics and point-of-care testing. The devices are protected by the Company's issued and pending patents, dealing with blood collection, analysis and plasma/serum processing.
The HemoPalm Handheld Blood Analyzer System is the only handheld blood analysis system, which combines Blood Gases & Electrolytes with full CO-oximetry. Currently this combination is not available on any of the handheld analyzers on the market. Existing technologies require users to purchase a second device to carry out the CO-oximetry. The Company's technology has the advantage of being able to offer a single handheld blood analyzer that provides all the required tests for Blood Gases & Electrolytes, with full CO-oximetry and bilirubin. Another competitive advantage of the HemoPalm system will be its ability to draw capillary blood directly from a pin-prick site into the cartridge, providing an alternative to arterial blood. Drawing arterial blood is painful and can cause nerve damage. CO-oximetry is the measurement of five different hemoglobin species in blood.
The global market for Blood Gases & Electrolytes was estimated to be 1.5 Billion $US in 2015 and is projected to reach over 1.8 Billion by 2020.
Website: www.chromedx.com
Contact:
Investor Relations
Office. 647-872-9982 ext. 2
TF. 1-844-247-6633 ext. 2
[email protected]
NEITHER THE CANADIAN SECURITIES EXCHANGE NOR ITS REGULATIONS SERVICES PROVIDER HAVE REVIEWED OR ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.
Forward-looking Information Cautionary Statement
Except for statements of historic fact, this news release contains certain "forward-looking information" within the meaning of applicable securities law. Forward-looking information is frequently characterized by words such as "plan", "expect", "project", "intend", "believe", "anticipate", "estimate" and other similar words, or statements that certain events or conditions "may" or "will" occur. Forward-looking statements are based on the opinions and estimates at the date the statements are made, and are subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ materially from those anticipated in the forward-looking statements including, but not limited to delays or uncertainties with regulatory approvals, including that of the CSE. There are uncertainties inherent in forward-looking information, including factors beyond the Company's control. The Company undertakes no obligation to update forward-looking information if circumstances or management's estimates or opinions should change except as required by law. The reader is cautioned not to place undue reliance on forward-looking statements. Additional information identifying risks and uncertainties that could affect financial results is contained in the Company's filings with Canadian securities regulators, which filings are available at www.sedar.com.
SOURCE: ChroMedX Corp.